Latest news with #LRP
Lebanon 24
17 hours ago
- Politics
- Lebanon 24
هذه إنجازات وزارة الشؤون خلال 100 يوم
وزعت وزارة الشؤون الاجتماعية انجازات الوزارة خلال 100 يوم وهي كالاتي: "برئاسة معالي الوزيرة حنين السيّد، وفي إطار حكومة دولة الرئيس نواف سلام ، أطلقت الوزارة ورشة إصلاح شاملة تهدف إلى تعزيز الحماية الاجتماعية، والإدماج، والتنمية، من خلال تحديث السياسات، وتغيير الهيكل المؤسسي، وتحسين الشفافية. Under the leadership of H.E. Minister Haneen El Sayed and within the framework of the government of Prime Minister Nawaf Salam, the Ministry launched a comprehensive reform effort aimed at strengthening social protection, inclusion, and development through updated policies, institutional change, and improved transparency. ١. رؤية جديدة للتنمية الاجتماعية 1. A New Vision for Social Development - إطلاق رؤية واستراتيجية الوزارة لعامي 2025–2026 – Launched the Ministry's 2025–2026 vision and strategy - الانتقال من تقديم المساعدة إلى التمكين – Shifted from assistance to empowerment - إعداد مشروع قانون لإعادة هيكلة الوزارة واقتراح تعديل اسمها إلى "وزارة التنمية الاجتماعية" – Prepared a draft law to restructure the Ministry and proposed renaming it the 'Ministry of Social Development' ٢. الحماية الاجتماعية تصل إلى آلاف الأسر 2. Social Protection Reaches Thousands of Families - تقديم مساعدات نقدية شهرية لحوالي 800 ألف مستفيد – Provided monthly cash assistance to approximately 800,000 beneficiaries - دعم مستمر لأكثر من 20,000 شخص من ذوي الإعاقة (0–30 سنة) – Continued support to over 20,000 persons with disabilities (ages 0–30) - العمل على توسيع التغطية لتشمل المسنين من ذوي الإعاقة – Working to expand coverage to include elderly persons with disabilities - توزيع أكثر من 60,000 حصة غذائية وصحية – Distributed more than 60,000 food and hygiene parcels ٣. شراكات لتعزيز الخدمات 3. Partnerships to Strengthen Services - توقيع شراكات جديدة مع وكالات الأمم المتحدة ومنظمات محلية – Signed new partnerships with UN agencies and local organizations - تأمين تمويل إضافي لشبكات الأمان الاجتماعي من المجتمع الدولي – Secured additional international funding for social safety nets - بدء اتفاقيات تعاون مع مصر، الأردن ، وقطر – Initiated cooperation agreements with Egypt, Jordan, and Qatar ٤. استجابة منسّقة للنزوح 4. Coordinated Displacement Response - قيادة جهود التنسيق ضمن خطة الاستجابة للأزمة اللبنانية (LRP) – Led coordination efforts under the lebanon Response Plan (LRP) - تطوير خطة وطنية للعودة من خلال لجنة وزارية – Advanced development of a national return plan through a ministerial committee - تقديم الدعم لـ 65 ألف عائلة لبنانية نازحة – Supported 65,000 displaced Lebanese families - توفير دعم مؤقت لـ 30 ألف عائلة متضررة بانتظار دمجها في برنامج أمان – Provided interim support to 30,000 conflict-affected families pending integration into the AMAN program ٥. الإدماج والحقوق للأشخاص ذوي الإعاقة 5. Inclusion and Rights for Persons with Disabilities - إعلان انتخاب الهيئة الوطنية لشؤون الأشخاص ذوي الإعاقة – Announced election of the National Commission for Persons with Disabilities - توقيع لبنان على الاتفاقية الدولية لحقوق الأشخاص ذوي الإعاقة – Signed the UN Convention on the Rights of Persons with Disabilities - تأمين دخول حاملي بطاقات الإعاقة إلى المستشفيات بالتعاون مع وزارة الصحة – Ensured hospital access for disability cardholders in cooperation with the Ministry of Public Health - دفع العمل على إصدار المراسيم التطبيقية للاتفاقيات الدولية – Pushed forward implementing decrees to realize international commitments ٦. الإدماج الاقتصادي وفرص العمل 6. Economic Inclusion and Employment Opportunities - اعتماد الإدماج الاقتصادي كمكوّن أساسي في برامج الوزارة – Adopted economic inclusion as a core pillar of MoSA programming - إطلاق وحدة للربط بسوق العمل بناءً على تقييم الأسر – Launched a job linkage unit based on household assessments - عقد شراكات مع القطاع الخاص لدعم التدريب والتوظيف – Partnered with the private sector to support training and employment - استهداف النساء، الشباب، والأشخاص ذوي الإعاقة من خلال برامج متخصصة – Targeted women, youth, and persons with disabilities through specialized programs ٧. الرقمنة والشفافية 7. Digitalization and Transparency - نشر بيانات المؤسسات المتعاقدة مع الوزارة على الموقع الإلكتروني لتعزيز الشفافية – Published online data on all welfare institutions contracted with the Ministry to enhance public transparency - رقمنة العمليات الداخلية وإطلاق إجراءات إلكترونية لتحسين جودة الخدمات – Digitized internal workflows and launched automation processes for better service delivery - تحديث وتوسيع السجل الاجتماعي الوطني (DAEM) لتحسين الاستهداف ودمج البرامج – Updated and expanded the National Social Registry (DAEM) to improve targeting and integration of social protection programs - تنسيق مع وزارة الداخلية ومشاركة بيانات الأشخاص ذوي الإعاقة لدمجهم في الانتخابات ضمن حملة "حقي 2025" – Coordinated with the Ministry of Interior to share disability cardholder data for electoral inclusion under the 'Haqi 2025' campaign ٨. الإصلاح والحوكمة لتعزيز الكفاءة 8. Reform and Governance to Improve Efficiency - مراجعة وتحديث عقود مؤسسات الرعاية لتحسين الجودة وضمان الاستدامة – Reviewed and updated contracts with care institutions to improve quality and ensure sustainability - تعزيز المراقبة والتقييم الميداني – Strengthened monitoring and field evaluation - تشكيل فريق لإعادة تصميم مراكز الخدمات الاجتماعية – Formed a task force to re-envision and redesign Social Development Centers (SDCs) - العمل على زيادة مخصصات الوزارة في موازنة 2026 – Worked to increase MoSA's 2026 budget allocation - توحيد معايير الجمعيات وتحسين آليات التدقيق – Standardized NGO criteria and improved audit mechanisms ٩. دعم التراث والحرفيين 9. Supporting Heritage and Artisans - إعادة إطلاق بيت المحترف اللبناني بعد تأهيله بالكامل – Relaunched the Lebanese Artisan House following full rehabilitation - تعيين هيئة جديدة ووضع خطة لدعم الحرفيين المحليين – Appointed a new board and developed a support plan for local artisans - تمكين النساء الريفيات وذوي الإعاقة من خلال الحرف اليدوية – Empowered rural women and persons with disabilities through traditional crafts وزارة الشؤون الاجتماعية – ١٠٠ يوم من العمل الفعلي Ministry of Social Affairs – 100 Days of Tangible Progress نحو مجتمع أكثر شمولاً، وعدالة، واستقراراً Towards a more inclusive, just, and stable society".
Yahoo
16-05-2025
- Business
- Yahoo
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL
PALO ALTO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, 'Scilex' or 'Company'), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today presented the presentation of post-hoc analysis of the C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) interpreting clinical meaningfulness of safety and efficacy of SP-102 (SEMDEXA™) for the treatment of lumbosacral radicular pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL. Poster Content: Interpreting Clinical Meaningfulness of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP): A Post-hoc Analysis of the CLEAR-1 Trial and A Systematic Review of Literature. . Authors: Miller AM, Knezevic NN, Nalamachu S, Meske D, Ambrose C, Vought K, Chan EK, and Lissin D. The poster is on display throughout the meeting from Thursday, May 15 through Saturday, May 17, 2025, allowing all attendees to view it. It is also available via the conference app and will be published in the Pain Physician journal. Interpretation of the clinical meaningfulness of results requires consideration of primary and secondary endpoints assessed with-in subject based on consensus benchmarks, and the between group differences in the context of the overall risk-benefit and in comparison, to other approved products for similar indications. The results of the CLEAR Trial show clear clinically meaningful separation between SP-102 and placebo in multiple with-in subject endpoints (NPRS Responder Analyses, ODI and BPI Pain Interference). This result is enhanced when solely considering a population that was confirmed to receive study drug by an independent expert (i.e., the mITT population). This trend is also observed in the magnitude of group mean differences, particularly when the standard effect size of SP-102 is compared to other marketed and approved analgesics for chronic low back pain (CLBP), as well as other TSIs. The formulation of SP-102 was intentionally created to offer a safer alternative to current off-label use of products that contain warnings of the potential dangerous and life-threatening adverse events. Collectively, the benefit-risk profile presented supports SP-102 being a safe and efficacious product that has the potential to offer much-needed therapy for the treatment of LRP. For more information on Scilex Holding Company, refer to For more information on Semnur Pharmaceuticals, Inc., refer to For more information on ZTlido®, including Full Prescribing Information, refer to For more information on ELYXYB®, including Full Prescribing Information, refer to For more information on Gloperba®, including Full Prescribing Information, refer to info@ About Scilex Holding Company Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex's commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the 'FDA') for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) ('SEMDEXA™' or 'SP-102'), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, ('SP-103'), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) ('SP-104'), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia. Scilex Holding Company is headquartered in Palo Alto, California. Forward-Looking Statements This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the presentation of post-hoc analysis of the C.L.E.A.R. trial (Corticosteroid Lumbar Epidural Analgesia in Radiculopathy) interpreting clinical meaningfulness of safety and efficacy of SP-102 (SEMDEXA™) for the treatment of lumbosacral radicular pain (LRP). Risks and uncertainties that could cause Scilex's actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: Scilex's ability to remain in compliance with the Nasdaq continued listing requirements and to maintain the listing of the Company's securities thereon; Scilex's ability to develop and commercialize treatments for obesity, neurodegenerative, and cardiometabolic disease; risks associated with the unpredictability of trading markets and whether a market will be established for Scilex's common stock; general economic, political and business conditions; risks related to COVID-19 (and other similar disruptions); the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex's product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex's product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex's most recent periodic reports filed with the Securities and Exchange Commission, including Scilex's Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file with the SEC, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law. Contacts: Investors and MediaScilex Holding Company 960 San Antonio RoadPalo Alto, CA 94303Office: (650) 516-4310 Email: investorrelations@ Website: SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned. ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company. ELYXYB® is a registered trademark owned by Scilex Holding Company. All other trademarks are the property of their respective owners. © 2025 Scilex Holding Company All Rights Reserved.
BBC News
10-03-2025
- Health
- BBC News
Lincolnshire health service warns over dangerous nitazene drugs
An addiction support service is warning about the danger of super-strength drugs that have been linked to a number of deaths across the Recovery Partnership (LRP), which is focussed on preventing overdoses, said it had seen a big increase in the use of nitazenes, which are synthetic opioids mixed into street drugs, such as Clifton, from the service's rough sleeper team, said: "People are not aware of what they're getting until they've used it and it's wiping them out. It's dangerous stuff."Recovering heroin addict Mark, not his real name, said users were playing Russian roulette due to not knowing what is in the drugs they are taking. "Every drug that you get that's in powder or tablet form will be cut with something. You haven't got a clue what's in it," he said. "It's Russian roulette."The 51-year-old, who was excluded from school at 14, left home and began using cannabis and later heroin, said his girlfriend overdosed in 2024 after taking a "speedball" - a mixture of cocaine, heroin and pharmaceutical said she survived after being rushed to hospital but claimed his neighbour was found dead last month after taking drugs. According to the Office for Health Improvement and Disparities, nitazenes are "typically many times stronger than heroin and carry a higher risk of overdose".In March 2024, the government added 15 synthetic opioids, including 14 types of nitazene, to the list of Class A drugs, while the Home Office said people convicted of supplying the substances would face "tough penalties".The latest figures, released by the Home Office in January, showed that since June 2023, there had been at least 400 drug-related deaths across the UK linked to nitazenes and said it expected this figure to increase in the coming Clifton, who is based in Boston, has been handing out warm clothes to rough sleepers as well as naloxone - a nasal spray that acts as an antidote to nitazene."I know people who have had an overdose but have not died from it simply because they had naloxone," he said."There has been a big increase in nitazene. We are hearing more about it from the people who access our service that it is becoming more prevalent."We need to make people aware that it's here and possibly here to stay." Police administering antidote Lincolnshire Police said its officers were being trained to use the antidote spray."It saves lives," said Richard Nethercott, temporary Ch Insp at South Holland station, near Boston."We are in a unique position as we are often first attending to the scene. If we come across someone who we feel has overdosed we can administer the spray."To help heroin users identify if they have a dose containing a nitazene, the LRP, which is funded by the local authority, has been handing out test strips that users can use to check for themselves."They (nitazenes) have become quite a big issue recently," said Emma Geal, who is a recovery worker at the partnership based in Gainsborough. "We have noticed a lot of people coming back saying it had nitazene in it. Some said they didn't use it, some people tested their heroin after and, unfortunately, they were not as lucky and did overdose."Mark has become a father for the first time and said his son was his motivation to stay off drugs and warn others of its said: "I don't want him to be anything like what I've been. I need to get this knowledge into his head before I expire." Listen to highlights from Lincolnshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here.
